Snapshot of the molecular targeted cancer therapies market in the rest of the world

Home

Snapshot of the molecular targeted cancer therapies market in the rest of the world

Commercial Insight: Molecular Targeted Cancer Therapies Leading companies will hold onto competitive advantage in high growth market

Molecular targeted cancer therapies are the biggest and fastest growing class of cancer drugs in terms of sales. As growth of revenues from cytotoxic therapies and antihormonal therapies has slowed and many key brands in these classes face imminent patent expiries, it is unsurprising that the major oncology companies have shifted their focus towards the molecular targeted cancer therapies market. ( http://www.bharatbook.com/detail.asp?id=104962&rt=Commercial-Insight-Molecular-Targeted-Cancer-Therapies-Leading-companies-will-hold-onto-competitive-advantage-in-high-growth-market.html )

Scope

* Forecast sales of every marketed molecular targeted cancer therapy in each of the seven major markets over the period 2008 to 2018
* Analysis and segmentation of the market at various levels including drug class, country, brand and company
* Comprehensive brand profiles and analysis for the key brands, including approval dates, patent expiries and all key events likely to impact sales
* Snapshot of the molecular targeted cancer therapies market in the rest of the world
Highlights

Total sales of marketed molecular targeted cancer therapies in the seven major pharmaceutical markets will grow at a CAGR of 9.8% from $17.5 billion in 2008 to $44.7 billion in 2018. Drivers of growth will include the continuing adoption of molecular targeted cancer therapies in currently approved indications and approvals in new indications.

Avastin (bevacizumab; Roche/Chugai) was the top-selling molecular targeted cancer therapy brand in 2008, and will remain the leading brand in 2018. Avastin will achieve this growth through indication expansion across a number of new tumor types and increasing uptake in new territories.

With a dominant presence in three of the four highest incidence solid tumors and the highest incidence hematological malignancy, Roche has established a stranglehold over the molecular targeted cancer therapies market. This will continue through to 2018, driven mainly by the strong performance of the company’s monoclonal antibody franchise.

Reasons to Purchase

* Quantify the performance of each of the marketed molecular targeted cancer therapies in the seven major markets over the period 2008 to 2018
* Assess the changing key opportunities and threats both for currently marketed and pipeline targeted therapy cancer brands
* Identify the leading brands in this market over the next 10 years and understand the key factors driving their success

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=104962&rt=Commercial-Insight-Molecular-Targeted-Cancer-Therapies-Leading-companies-will-hold-onto-competitive-advantage-in-high-growth-market.html

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook

We are the leading information aggregator, facilitates and supports the business information needs. With over 115,000 reports, you can get instant access and insights on the studies in yo for market research , corporate / strategic planning by providing the latest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management, country intelligence, consumer & durable goods, chemical and more ur areas of interest. Contact us at +91 22 27578668 / 27579438 or email info@bharatbook.com or our website www.bharatbook.com

Article Source:http://www.articlesbase.com/cancer-articles/snapshot-of-the-molecular-targeted-cancer-therapies-market-in-the-rest-of-the-world-1524935.html

Cancer drugs fail to win NHS funding (pharmastrategyblog.com)
Gene library to help Dalhousie scientists fight cancer (cbc.ca)
Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline (newswire.ca)
Light The Night for Cancer (takepart.com)
Analyzing Cancer Cells to Choose Treatments (technologyreview.com)
The Algebra of Need: Cancer, Biologics, PhRMA (firedoglake.com)
Tamoxifen linked to risk of aggressive cancer (thestar.com)
Vanderbilt scientists report first effective medical therapy for rare stomach disorder (scienceblog.com)

Tagged with: bevacizumab, Business, cancer, Conditions and Diseases, Health, Monoclonal antibodies, Oncology, Targeted therapy

Read also:

December 27th, 2009 | Category: cancer information | Comments Off
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.

Cancer Information